TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04185077
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
Study: NCT00752921
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg
Study: NCT00752921
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04090957
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet will be administered orally once daily.
Study: NCT00437489
Drug: Inhaled Human Insulin (Exubera)
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
Study: NCT00437489
Drug: Inhaled Human Insulin (Exubera)
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 1mg TID of inhaled human insulin
Study: NCT03930771
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
Study: NCT01779336
Drug: PL225B
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified.
Study: NCT01491061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: os, two doses 12 hours apart prior to PCI
Study: NCT02899455
Drug: HGP0904
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899455
Drug: HGP0608
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899455
Drug: HGP0816
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899455
Drug: HGP0904 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899455
Drug: HGP0816 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03276728
Drug: Placebo PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets for oral administration
Study: NCT03276728
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo solution for infusion
Study: NCT01506635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: artificial tear twice a day
Study: NCT04447235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
Study: NCT01575639
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
Study: NCT00216151
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid 4mg, every three months
Study: NCT02079909
Drug: T-817MA-H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 224 mg or 448 mg T-817 MA once daily
Study: NCT02079909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03805932
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg Cycle 1, Day -2, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
Study: NCT04498650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
Study: NCT01374321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
Study: NCT04552041
Drug: Prospekta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT04552041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT03427814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg orally twice daily
Study: NCT03365817
Drug: Opioids taper off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
Study: NCT03365817
Drug: Opioid stable treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No changes on prescribed opioids and adjuvant medication for the next six months
Study: NCT00598923
Drug: phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
Study: NCT00294671
Drug: diflunisal
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given twice daily for 24 months
Study: NCT04020133
Drug: 0.05 mg epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
Study: NCT01955707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT01255839
Drug: Minprostin
Normalized name: Minprostin F2 Alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prostaglandin 2 minprostin (3mg) was applied vaginally
Study: NCT00115271
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00332579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT01618058
Drug: No Investigational Product
Normalized name: No Doz Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants
Study: NCT04120246
Drug: Alpha-tocopheryloxyacetic Acid
Normalized name: ALPHA-TOCOPHERYLOXYACETIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03962907
Drug: BACTROBAN® Nasal ong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
Study: NCT04266392
Drug: [18F]-DCFPyl Ligand
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
Study: NCT03831178
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
Study: NCT00600275
Drug: BGT226
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00293813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for alendronate and placebo for denosumab
Study: NCT01498744
Drug: Oral Clindamycin
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
Study: NCT03979469
Drug: fentanyl, remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
Study: NCT02140970
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
Study: NCT02140970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
Study: NCT04294459
Drug: Acetaminophen (paracetamol) or equivalent
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablets~Route of administration: Oral
Study: NCT04294459
Drug: Methylprednisolone or equivalent
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution~Route of administration: Intravenous
Study: NCT01413243
Drug: Trichuris suis ova
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichuris suis ova 2500 eggs every 2 weeks
Study: NCT00460655
Drug: GSK1358820
Approvals — FDA: no, EMA: no, PMDA: no
Description: botulinum toxin type A
Study: NCT00460655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00128024
Drug: lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03797066
Drug: ZEPATIER 50Mg-100Mg Tablet
Normalized name: ZEPATIER 50mg-100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
Study: NCT00400218
Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00855777
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg/day for 3 days
Study: NCT00855777
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 1,800 mg/day for 3 days
Study: NCT00655928
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 1 litre intravenous over 12 hours pre-operatively
Study: NCT03146988
Drug: RGB-02 or Neulasta® (pegfilgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
Study: NCT00079261
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00079261
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00079261
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04347512
Drug: Hydroxychloroquine and azithromycin treatment arm.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
Study: NCT00648921
Drug: Zyprexa® Tablets 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, single dose fasting
Study: NCT01014767
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3
Study: NCT01014767
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
Study: NCT01014767
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
Study: NCT01014767
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
Study: NCT03198767
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.
Study: NCT00330707
Drug: Bacillus Calmette Guerin and interferon alpha
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04551963
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules administered at a dose and frequency as specified in the treatment arm
Study: NCT02227030
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03425812
Drug: To withdraw NSAIDs therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs therapy will be withdrew after washout period.
Study: NCT04019743
Drug: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fasting condition
Study: NCT04019743
Drug: CKD-333 16/10/40mg formulation 1 Tab. 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fasting condition
Study: NCT04019743
Drug: CKD-333 16/10/40mg formulation 2 Tab. 1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration under fasting condition
Study: NCT02227030
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02890745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01132846
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
Study: NCT02831855
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.
Study: NCT02831855
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.
Study: NCT02831855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
Study: NCT02219932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT02540512
Drug: hydrocodone / acetaminophen 5mg/325mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic/NSAID medication used as the standard medical treatment
Study: NCT02540512
Drug: Placebo Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills will be filled with methylcellulose and administered as a placebo for this intervention.
Study: NCT04098653
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT00163241
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02010593
Drug: Placebo Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
Study: NCT02374281
Drug: Glucose sucking
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01098448
Drug: local tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm
Study: NCT04424459
Drug: opioid withdrawal
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
Study: NCT04428788
Drug: CC1083611
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04428788
Drug: CC1083610
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04323280
Drug: NSAID therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
Study: NCT00070265
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03018535
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
Study: NCT00956722
Drug: Bovine Colostrum Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine Colostrum Powder (Biogard)
Study: NCT03116906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to be given for a total of up to 15 days
Study: NCT00912990
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Intravenous dose
Study: NCT02531360
Drug: [18F]MNI-815 (MNI-815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
Study: NCT04505644
Drug: IV saline infusion +Sham patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
Study: NCT04704297
Drug: Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.
Approvals — FDA: no, EMA: no, PMDA: no
Description: We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
Study: NCT04704297
Drug: Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
Study: NCT04704297
Drug: Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
Study: NCT02141230
Drug: Alli® 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants purchasing Alli®
Study: NCT02373046
Drug: LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
Study: NCT02373046
Drug: LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
Study: NCT01224327
Drug: Conserved therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or intravenous administration
Study: NCT00324467
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Study: NCT00324467
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan
Study: NCT00324467
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion